American Association for Cancer Research
Browse (699.54 kB)

Supplementary Figure. S5 from GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models

Download (699.54 kB)
posted on 2023-03-31, 20:27 authored by Mojgan Shourideh, Gissou Azabdaftari, Kristopher Attwood, Adam DePriest, Kristine M Wadosky, Bryan M Gillard, Ellen Karasik, Hannelore Heemers, Natasha Kyprianou, Irwin H. Gelman, Eva Corey, Robert L Vessella, James L. Mohler, Shahriar Koochekpour

DHT upregulation of GRM1 expression is AR-dependent.


HHS | NIH | National Cancer Institute (NCI)



Purpose:We recently demonstrated that glutamate receptor GRM1 was expressed at high levels in castration-resistant prostate cancer (CR-PCa) tissues and cells. Herein, we determined the relationship between GRM1 and AR, PSA, and tumor growth, remission, and recurrence in preclinical PCa models. The effect of alterations in GRM1 expression was also investigated on PCa cell growth, migration and invasion. Experimental Design:We used quantitative gene expression and immunohistochemistry to define the temporal association between GRM1 expression and AR, PSA, and tumor growth during CR progression in CWR22 (n = 59) and LuCaP 35 (n = 12) PCa xenografts. The effect of alterations in GRM1 expression levels on growth, migration, and invasion was investigated in GRM1-overexpressed or -silenced PCa cell lines. The effect of DHT on GRM1 expression was determined in the presence or absence of the antiandrogen bicalutamide. Results:We found that GRM1 transcript and tissue expression directly correlated with growth and AR and PSA expression in hormone-sensitive (HS), castrated, and CR tumor xenografts. GRM1 overexpression or silencing directly correlated with PCa cell proliferation, migration, and invasion. DHT increased GRM1 expression via an AR-dependent manner in HS- and CR-PCa cell lines. Conclusions:This is a first report of GRM1 as an androgen and AR-target gene. GRM1 expression directly correlated with tumor growth, regression, and recurrence and may contribute to CR-progression of PCa in preclinical models. Further studies are needed to define the utility of GRM1 as a druggable target or biomarker for PCa.

Usage metrics

    Clinical Cancer Research





    Ref. manager